| Entry |
|
|---|
| Name |
Glibornuride (USAN/INN);
Glutril (TN) |
|---|
| Formula |
C18H26N2O4S
|
|---|
| Exact mass |
366.1613
|
|---|
| Mol weight |
366.475
|
|---|
| Structure |
|
|---|
| Class |
|
|---|
| Remark |
|
|---|
| Efficacy |
Antidiabetic, Hypoglycemic, Sulfonylurea receptor agonist |
|---|
| Comment |
Sulfonylurea
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07018 | Sulfonamide derivatives - hypoglycemic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BB Sulfonylureas
A10BB04 Glibornuride
D02427 Glibornuride (USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01508 Sulfonylurea receptor agonist
DG01734 Sulfonylurea
D02427 Glibornuride
DG02044 Hypoglycemic agent
DG01734 Sulfonylurea
D02427 Glibornuride
Target-based classification of drugs [BR:br08310]
Transporters
ABC transporters
ABCC subfamily
ABCC8 (SUR1)
D02427 Glibornuride (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 25
1 C1z C 27.7996 -16.7237
2 S4a S 21.5497 -20.1287
3 N1b N 23.0422 -20.8283
4 C5a C 24.0683 -20.1287
5 N1b N 25.2344 -20.7350
6 O5a O 24.0683 -18.8227
7 C1y C 26.3071 -20.0353
8 C1y C 27.3799 -19.2425
9 C1y C 25.7474 -18.8227
10 C1z C 26.6337 -17.8899
11 C1x C 28.6392 -19.4756
12 C1x C 27.9862 -18.1231
13 C1a C 29.1056 -16.4439
14 C1a C 27.2866 -15.4644
15 C1a C 25.7474 -17.0037
16 O1a O 24.7213 -17.9365
17 O3c O 20.5597 -19.1387
18 O3c O 22.5396 -19.1387
19 C8y C 20.3373 -20.8287
20 C8x C 19.1628 -20.1510
21 C8x C 17.9505 -20.8513
22 C8y C 17.9509 -22.2513
23 C8x C 19.1253 -22.9290
24 C8x C 20.3376 -22.2287
25 C1a C 16.7118 -22.9673
BOND 27
1 2 3 1
2 3 4 1
3 4 5 1
4 4 6 2
5 5 7 1
6 7 8 1
7 7 9 1
8 9 10 1
9 8 11 1
10 10 12 1
11 12 11 1
12 1 8 1
13 10 1 1
14 1 13 1
15 1 14 1
16 10 15 1
17 9 16 1
18 2 17 2
19 2 18 2
20 2 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 19 24 1
27 22 25 1
|
|---|
